Apimeds Pharmaceuticals US, Inc. (NYSE MKT:APUS) — Market Cap & Net Worth
Market Cap & Net Worth: Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (NYSE MKT:APUS) has a market capitalization of $2.47 Million ($2.47 Million) as of September 17, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #29843 globally and #6083 in its home market, demonstrating a -32.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apimeds Pharmaceuticals US, Inc.'s stock price $1.64 by its total outstanding shares 1509117 (1.51 Million). Also see Apimeds Pharmaceuticals US, Inc. total assets for a full breakdown of the balance sheet.
Apimeds Pharmaceuticals US, Inc. Market Cap History: 2025 to 2026
Apimeds Pharmaceuticals US, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $2.47 Million to $2.47 Million (0.00% CAGR). Also see Apimeds Pharmaceuticals US, Inc. cash flow conversion for how efficiently the company converts equity into cash flow.
Apimeds Pharmaceuticals US, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apimeds Pharmaceuticals US, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Apimeds Pharmaceuticals US, Inc. (APUS) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of APUS by Market Capitalization
Companies near Apimeds Pharmaceuticals US, Inc. in the global market cap rankings as of September 17, 2026. Review how tangible is Apimeds Pharmaceuticals US, Inc.'s equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Apimeds Pharmaceuticals US, Inc. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Apimeds Pharmaceuticals US, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Apimeds Pharmaceuticals US, Inc.'s market cap moved from $2.47 Million to $ 2.47 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.47 Million | 0.00% |
| 2025 | $2.47 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Apimeds Pharmaceuticals US, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.47 Million USD |
| MoneyControl | $2.47 Million USD |
| MarketWatch | $2.47 Million USD |
| marketcap.company | $2.47 Million USD |
| Reuters | $2.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.